Merkel Cell Carcinoma - prIME Oncology
Expert Review
Expert Review

Merkel Cell Carcinoma

Grappling With the Evolving Role of Immunotherapy

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Watch leading experts give a comprehensive review of immunotherapy in merkel cell carcinoma (MCC). Gain insight into current standard of care for advanced MCC, emerging immunotherapy agents, and the role of immunotherapy in early-stage disease.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Nov 28, 2018

Expiration Date

Nov 28, 2019

  • Axel Hauschild, MD, PhDUniversity Hospital Schleswig-Holstein
    Kiel, Germany
  • Paul Nathan, MBBS, BSc (Hons), PhD, FRCPMount Vernon Cancer Centre
    Northwood, United Kingdom
  • Caroline Robert, MD, PhDInstitut Gustave-Roussy
    Villejuif, France
  • Scope of the problem (diagnostic challenges, pathogenesis, high propensity of recurrence after local treatment, immunogenicity)
  • Current management of advanced MCC
  • Emerging immunotherapy agents in development
  • Moving immunotherapy in early-stage disease

This virtual educational activity is designed to meet the needs of healthcare professionals involved and/or interested in the therapeutic management of patients with Merkel cell carcinoma, including practicing oncologists, dermatologists, surgeons, nurses, and researchers.

After successful completion of this educational activity, participants should be able to:

  • Identify clinical and pathogenesis-related factors of MCC, and evaluate their impact on treatment decision making
  • Evaluate current and emerging efficacy and safety data, as well as ongoing clinical trials investigating immune checkpoint inhibitors in MCC
  • Discuss optimal treatment strategies for individual patients with MCC

This educational activity is supported by a grant from Merck KGaA and Pfizer.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Hauschild has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, MerckSerono, MSD/Merck, Novartis, OncoSec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi-Genzyme, and Sun Pharma. He has spoken and taught for Amgen, Bristol-Myers Squibb, MSD/Merck, Novartis, Pierre Fabre, Provectus, Roche, and Sanofi-Genzyme. He has also received clinical trial support (grant to institution) from Amgen, Bristol-Myers Squibb, MerckSerono, MSD/Merck, Novartis, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, and Sanofi-Genzyme. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nathan has disclosed membership on advisory committees or review panels for AstraZeneca, Bristol-Meyer Squibb, Immunocore, MSD, Novartis, Pfizer, Pierre Fabre, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Robert has disclosed that she has been on advisory boards and received consulting fees from Bristol-Meyer Squibb, MSD, Novartis, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.